In a study, a nanovesicle was designed by engineering tumor cell-derived exosomes with the fibroblast activation protein-α (FAP) gene, with the purpose of serve as a tumor vaccine and to overcome the immunosuppressive characteristics of TME. This evidence concerns the gene FAP and neoplasm.